Shayne A. Bellingham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shayne A. Bellingham has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Francis Hill
Institute for Health and Sport Victoria University Melbourne Australia
4 shared publications - Belinda B. Guo
School of Biomedical Sciences University of Western Australia Crawley WA Australia
2 shared publications - Anthony Robert White
Brain and Mental Health Program, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia
1 shared publication - Ashley Ian Bush
The University of Melbourne
1 shared publication - Bradley M. Coleman
Department of Biochemistry and Molecular Biology, The University of Melbourne Melbourne, VIC 3010, Australia
1 shared publication - Camelia Quek
Melanoma Institute Australia, The University of Sydney, Sydney, Australia
1 shared publication
Latest Publications
- Open Access
- 1 February 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (6) , 3455-3467
The Neutral Sphingomyelinase Pathway Regulates Packaging of the Prion Protein into Exosomes
- 1 February 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (6) , 3455-3467
Open AccessThe Neutral Sphingomyelinase Pathway Regulates Packaging of the Prion Protein into Exosomes
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 4, 150
The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies
Diagnostic tools for neurodegenerative diseases such as Alzheimer's disease (AD) currently involve subjective neuropsychological testing and specialized brain imaging techniques. While definitive diagnosis requires a pathological brain evaluation at autopsy, neurodegenerative changes are believed to begin years before the clinical presentation of cognitive decline. Therefore, there is an essential need for reliable biomarkers to aid in the early detection of disease in order to implement preventative strategies. microRNAs (miRNA) are small non-coding RNA species that are involved in post-transcriptional gene regulation. Expression levels of miRNAs have potential as diagnostic biomarkers as they are known to circulate and tissue specific profiles can be identified in a number of bodily fluids such as plasma, CSF and urine. Recent developments in deep sequencing technology present a viable approach to develop biomarker discovery pipelines in order to profile miRNA signatures in bodily fluids specific to neurodegenerative diseases. Here we review the potential use of miRNA deep sequencing in biomarker identification from biological fluids and its translation into clinical practice.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 4, 150
Open AccessThe detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies
Diagnostic tools for neurodegenerative diseases such as Alzheimer's disease (AD) currently involve subjective neuropsychological testing and specialized brain imaging techniques. While definitive diagnosis requires a pathological brain evaluation at autopsy, neurodegenerative changes are believed to begin years before the clinical presentation of cognitive decline. Therefore, there is an essential need for reliable biomarkers to aid in the early detection of disease in order to implement preventative strategies. microRNAs (miRNA) are small non-coding RNA species that are involved in post-transcriptional gene regulation. Expression levels of miRNAs have potential as diagnostic biomarkers as they are known to circulate and tissue specific profiles can be identified in a number of bodily fluids such as plasma, CSF and urine. Recent developments in deep sequencing technology present a viable approach to develop biomarker discovery pipelines in order to profile miRNA signatures in bodily fluids specific to neurodegenerative diseases. Here we review the potential use of miRNA deep sequencing in biomarker identification from biological fluids and its translation into clinical practice.
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 3, 124
Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?
Exosomes are small membranous vesicles secreted by a number of cell types including neurons and can be isolated from conditioned cell media or bodily fluids such as urine and plasma. Exosome biogenesis involves the inward budding of endosomes to form multivesicular bodies (MVB). When fused with the plasma membrane, the MVB releases the vesicles into the extracellular environment as exosomes. Proposed functions of these vesicles include roles in cell–cell signaling, removal of unwanted proteins, and the transfer of pathogens between cells. One such pathogen which exploits this pathway is the prion, the infectious particle responsible for the transmissible neurodegenerative diseases such as Creutzfeldt–Jakob disease (CJD) of humans or bovine spongiform encephalopathy (BSE) of cattle. Similarly, exosomes are also involved in the processing of the amyloid precursor protein (APP) which is associated with Alzheimer’s disease. Exosomes have been shown to contain full-length APP and several distinct proteolytically cleaved products of APP, including Aβ. In addition, these fragments can be modulated using inhibitors of the proteases involved in APP cleavage. These observations provide further evidence for a novel pathway in which PrP and APP fragments are released from cells. Other proteins such as superoxide dismutase I and alpha-synuclein (involved in amyotrophic lateral sclerosis and Parkinson’s disease, respectively) are also found associated with exosomes. This review will focus on the role of exosomes in neurodegenerative disorders and discuss the potential of these vesicles for the spread of neurotoxicity, therapeutics, and diagnostics for these diseases.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 3, 124
Open AccessExosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?
Exosomes are small membranous vesicles secreted by a number of cell types including neurons and can be isolated from conditioned cell media or bodily fluids such as urine and plasma. Exosome biogenesis involves the inward budding of endosomes to form multivesicular bodies (MVB). When fused with the plasma membrane, the MVB releases the vesicles into the extracellular environment as exosomes. Proposed functions of these vesicles include roles in cell–cell signaling, removal of unwanted proteins, and the transfer of pathogens between cells. One such pathogen which exploits this pathway is the prion, the infectious particle responsible for the transmissible neurodegenerative diseases such as Creutzfeldt–Jakob disease (CJD) of humans or bovine spongiform encephalopathy (BSE) of cattle. Similarly, exosomes are also involved in the processing of the amyloid precursor protein (APP) which is associated with Alzheimer’s disease. Exosomes have been shown to contain full-length APP and several distinct proteolytically cleaved products of APP, including Aβ. In addition, these fragments can be modulated using inhibitors of the proteases involved in APP cleavage. These observations provide further evidence for a novel pathway in which PrP and APP fragments are released from cells. Other proteins such as superoxide dismutase I and alpha-synuclein (involved in amyotrophic lateral sclerosis and Parkinson’s disease, respectively) are also found associated with exosomes. This review will focus on the role of exosomes in neurodegenerative disorders and discuss the potential of these vesicles for the spread of neurotoxicity, therapeutics, and diagnostics for these diseases.
- 5 November 2010
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 4 (10-11) , 851
A domain level interaction network of amyloid precursor protein and Aβ of Alzheimer's disease
- 5 November 2010
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 4 (10-11) , 851
A domain level interaction network of amyloid precursor protein and Aβ of Alzheimer's disease